AccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development Agreement and Strategic Partnership
LONDON and PHOENIX, July 17, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, and EmeritusDX, a rapidly
GlobeNewswireJul 17, 2023 07:00 ET
AccuStem Sciences, Inc. Extends and Broadens Partnership With Instituto Europeo Di Oncologia (IEO) Enabling Its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer
StemPrintER outperformed the current market leader, OncotypeDX test, in stratifying patients according to their risk of breast cancer recurrence LONDON and PHOENIX, July 11, 2023 (GLOBE NEWSWIRE) -- AccuStem
GlobeNewswireJul 11, 2023 07:00 ET
Goldman Small Cap Research Publishes New Research Report on AccuStem Sciences, Inc.
BALTIMORE, MD / ACCESSWIRE / June 20, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new re
AccesswireJun 20, 2023 08:09 ET
AccuStem Sciences, Inc. Announces Collaboration Agreement With University Hospitals
AccuStem Sciences, Inc. (OTCQB: ACUT) today announced the establishment of a joint clinical collaboration agreement with University Hospitals.
GlobeNewswireJun 6, 2023 01:00 ET
AccuStem Announce Strategic Clinical and Operational Partnership
LONDON and PHOENIX, May 31, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today annou
GlobeNewswireMay 31, 2023 07:00 ET
AccuStem Sciences Announces Extension of Its US Patent Application for SPARE Test for Patients With Breast Cancer
LONDON and PHOENIX, May 02, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced t
GlobeNewswireMay 2, 2023 07:12 ET
Cancer Diagnostics Maker Accustem Files for Nasdaq Uplisting, $11M Offering
Seeking AlphaJan 20, 2023 20:07 ET
AccuStem Sciences Announces Appointment of Sean McDonald to Board of Directors
LONDON and PHOENIX, Nov. 16, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced
GlobeNewswireNov 16, 2022 07:05 ET
AccuStem Announces Adjournment of Annual Meeting of Stockholders
LONDON and PHOENIX, Oct. 10, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced t
GlobeNewswireOct 10, 2022 16:20 ET
AccuStem Sciences Announces Issuance of US Patent for StemPrintER Test for Patients With Breast Cancer
LONDON and PHOENIX, Ariz., Sept. 13, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, an
GlobeNewswireSep 13, 2022 09:06 ET
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
LONDON and PHOENIX, April 28, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified
GlobeNewswireApr 28, 2022 08:47 ET
4 Stocks Under $2 Insiders Are Aggressively Buying
US crude oil futures traded lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concer
Benzinga Real-time NewsApr 28, 2022 08:20 ET
AccuStem Announces Private Placement of Common Stock
LONDON and PHOENIX, April 05, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTC Pink: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that it h
GlobeNewswireApr 5, 2022 12:36 ET
AccuStem Sciences, Inc. Announces DTC Eligibility
LONDON and PHOENIX, March 23, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTC Pink: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, is pleased to annou
GlobeNewswireMar 23, 2022 07:43 ET
No Data
No Data